The company’s sales for the first quarter of FY2027 were \u00a529.7 billion, a decrease of \u00a55.75 hundred million YoY; operating profit was \u00a51.0 billion, down \u00a51.4 hundred million; net profit was \u00a5824 million, a 60.8% decline. Sales were affected by a decrease in domestic new pharmaceuticals.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4569-20260730-02.pdf","jir_short_summary":"The company's sales for the first quarter of FY2027 were \u00a529.7 billion, a decrease of \u00a55.75 hundred million YoY; operating profit was \u00a51.0 billion, down \u00a51.4 hundred million; net profit was \u00a5824 million, a 60.8% decline. Sales were affected by a decrease in domestic new pharmaceuticals.","jir_summary":"### Summary of Business Performance\nThe consolidated sales for the first quarter of FY2027 were \u00a529.7 billion, a decline of \u00a55.75 hundred million YoY, mainly due to a decrease in sales of domestic new pharmaceuticals. Operating profit was \u00a51.0 billion, down \u00a51.44 hundred million, and net profit also dropped significantly to \u00a5824 million. Increased costs and drug price revisions compressed profit margins.\n\n### Outlook and Investor Impact\nThe company continues to promote the expansion of new drug sales and cost management, but the downward trend in sales and profits persists. The progress rate for Q2 is projected at 51.3% for sales and 48.2% for operating profit, making careful consideration of full-year forecasts necessary. Investors should monitor performance recovery trends and progress in new drug development.","jir_financial_highlights":"Sales: \u00a529.7 billion (YoY -\u00a55.75 hundred million)\nOperating Income: \u00a51.0 billion (YoY -\u00a51.44 billion)\nNet Income Attributable to Owners of Parent: \u00a5824 million (YoY -60.8%)","jir_category":"","jir_hashtags":"#JapaneseCompany, #FinancialResults, #IR, #Pharmaceuticals","jir_key_figures":"Sales: \u00a529.7 billion (YoY -\u00a55.75 hundred million)\nOperating Income: \u00a51.0 billion (YoY -\u00a51.44 billion)\nNet Income Attributable to Owners of Parent: \u00a5824 million (60.8% decrease)","jir_meta_title":"\u3010Unknown\u3011Q1 FY2027 Financial Results\uff5cSales \u00a529.7 billion (YoY -1.9%)","jir_meta_description":"Detailed explanation of the company's Q1 FY2027 financial results. Analysis of factors behind sales of \u00a529.7 billion and net profit of \u00a5824 million, and outlook for the future for investors.","jir_og_title":"\u3010Unknown\u3011Q1 FY2027 Earnings\uff5cSales \u00a529.7 billion, Net Profit \u00a5824 million decrease","jir_og_description":"Overview of the Q1 FY2027 financial results and future outlook for investors. Focus on sales and profit trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90549","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n